The changes driving Cancer Progression

Despite decades of research, cancer remains one of the most complex challenges in modern medicine.The difficulty stems from its dynamic nature: it is not a single disease, but an evolutionary process fueled by profound transformations in cell behavior.

Understanding these steps is essential to grasp why therapies targeting a single mechanism are often insufficient and why the most promising strategies today aim to hit multiple biological pathways simultaneously.

The first fundamental change is self-sufficiency in growth signals.

Healthy cells divide only when they receive specific instructions from the body. Tumor cells, however, bypass this control: through genetic mutations, they begin producing growth factors autonomously or keep cell receptors constantly active. The result is uncontrolled proliferation that ignores normal biological brakes.

The second key element is evasion of programmed cell death, or apoptosis.

Under normal conditions, a damaged or aged cell activates a self-destruction mechanism, a sort of internal safety system. Tumor cells manage to disable this process, becoming essentially “immortal” and accumulating further mutations without being eliminated.

A third crucial step involves cellular metabolism, known as the Warburg effect.

To sustain rapid growth, the tumor alters its energy production method, consuming large amounts of glucose and generating energy even in the absence of oxygen. This adaptation not only fuels proliferation but also creates an acidic microenvironment that favors the tumor and hinders surrounding healthy tissues.

Finally, angiogenesis—the formation of new blood vessels—plays a decisive role.

A tumor mass cannot expand beyond a certain size without an adequate supply of nutrients. To overcome this limit, the tumor releases chemical signals that induce the body to build new vessels directed toward the mass, ensuring constant supplies and paving the way for metastatic spread.

These four biological drivers explain why a single treatment is rarely enough. The extraordinary plasticity of tumor cells allows them to adapt: if a drug blocks one mechanism, others can compensate.

Targeting a single pathway is like closing one door in a room full of exits.

For this reason, the most advanced therapies combine different approaches: angiogenesis inhibitors to limit nutrients, drugs that reactivate apoptosis, and immunotherapies that help the immune system recognize and attack diseased cells.

The true challenge of precision medicine is to identify, for each patient, which mechanisms predominate, so as to shut down the processes sustaining the disease simultaneously and reduce the risk of resistance. Only a coordinated, multi-systemic action can effectively counter a pathology that makes adaptation its most powerful weapon.

Editorial by Prof. Antonio Giordano